Profile cover photo
Profile photo
Protalex, Inc.
4 followers -
Protalex, Inc. (OTCQB: PRTX) is focused on the development of a class of drugs for treating a wide array of autoimmune and inflammatory diseases.
Protalex, Inc. (OTCQB: PRTX) is focused on the development of a class of drugs for treating a wide array of autoimmune and inflammatory diseases.

4 followers
About
Posts

Post has attachment

Post has attachment
Protalex has initiated enrollment in its fifth and final cohort of its European Phase 1B study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP). The first patient in this final cohort was recently dosed in the United Kingdom at 24.0 µg/kg, the highest dose used in any clinical trial to date. Read the release for details:
Add a comment...

Post has attachment
Protalex has initiated enrollment in the fourth cohort of its European Phase 1B study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study). The first patient in this penultimate cohort was recently dosed in the United Kingdom at 18.0 µg/kg, the highest dose of PRTX-100 used in any clinical trial to date. For details please visit:
Add a comment...

Post has attachment
Protalex today announced that preclinical data showing its lead drug candidate PRTX-100 increases blood platelet counts in a murine model of immune thrombocytopenia (ITP) were published in the recent issue of the peer-reviewed journal, British Journal of Haematology, in an article titled, “A highly purified form of Staphylococcal protein A alleviates murine immune thrombocytopenia.” Read the full release for details: http://bit.ly/2yO3q2q
Add a comment...

Post has attachment
Protalex today announced that following a planned interim analysis of data from the second dose cohort of its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP), the Company has initiated enrollment in the third cohort of this dose-escalating study. The first patient in the third cohort was recently dosed at 12.0 µg/kg, double that of the second dose cohort of 6.0 µg/kg. Richard J. Francovitch, Ph.D., Vice President, ITP Programs at Protalex, commented, “Initiating the third dose cohort of the PRTX-100-203 Study is an important milestone as Protalex evaluates the activity of PRTX-100 across a broad range of doses."
Add a comment...

Post has attachment
Protalex has been awarded a $403,000 grant from the FDA's Office of Orphan Products Development (OOPD) to support future clinical development activity of PRTX-100 as a treatment for Immune Thrombocytopenia (ITP). Protalex President, Arnold P. Kling, commented, "The FDA provides grants for clinical studies on safety and/or effectiveness that will hopefully result in or substantially contribute to market approval of these candidate drugs. Given that this FDA program has been used in the past to bring more than 60 drugs to market, we are encouraged by their support and the promise that PRTX-100 holds in treating ITP as well as other autoimmune diseases." Read the full release for details:
Add a comment...

Post has attachment
Protalex announced that following completion of a planned interim analysis of safety & efficacy data from the 2nd dose cohort, Protalex is escalating the dose of PRTX-100 in its U.S. Phase 1/2 study in adults with ITP. Dr. Richard Francovitch, Protalex’s VP ITP Programs, commented, "Protalex is pleased that patient enrollment into the second dose cohort of the PRTX-100-202 Study has been completed and that one patient from the cohort responded to treatment with PRTX-100. Since responses have been observed in each of the completed cohorts, we look forward to the results of treatment in the new cohort as Protalex evaluates the activity of PRTX-100 across a broad range of doses." Full release:
Add a comment...

Post has attachment
President & CEO, Arnold P. Kling issued a Letter to Shareholders providing a business update. "Protalex started 2017 with several advances to our global clinical development programs of our lead product, PRTX-100, a highly-purified form of Staphylococcal protein A (SpA), as a potentially safe and effective new treatment for autoimmune diseases, that position us for continued advancement throughout the balance of the year and beyond," noted Kling. Click to read the full Shareholder Letter.
Add a comment...

Post has attachment
Protalex significantly strengthens global intellectual property portfolio with the addition of six key international patents protecting and expanding use for PRTX-100. “We continue to invest in expanding our global intellectual property portfolio as part of our commitment to broadly protect our proprietary immunomodulatory SpA technology. We are fortifying our patent estate to support our comprehensive strategy for the development and commercialization of PRTX-100 in a variety of autoimmune and inflammatory diseases,” stated Protalex President, Arnold Kling.
Add a comment...

Post has attachment
Protalex provided an update on its U.S. Phase 1/2 and European Phase 1b studies of PRTX-100 in adults with persistent, chronic Immune Thrombocytopenia (ITP). Dr. Richard Francovitch, Protalex’s VP ITP Programs, commented, “to meet the challenge of patient enrollment associated with a rare disease like ITP, especially in a population that has not responded adequately to current therapies, we have expanded the number of clinical sites markedly. With this expansion, we will soon have more than 20 sites worldwide for patient enrollment. We look forward to completing the second cohorts in the 202 and 203 studies and to advancing to the next cohort in each study.”
Add a comment...
Wait while more posts are being loaded